The most common TRAE were anemia (in 10 [32.4%] of patients treated with Disitamab Vedotin combined with ICIs, and in 3 [20%] of patients treated with Disitamab Vedotin alone), elevated aspartate transaminase (AST) /alanine aminotransferase (ALT), hypoalbuminemia, and nausea. The gene discussed is GPT; the disease is Hypoalbuminemia.